Don't worry OSS...All the good HSS reps are planning on quitting soon

Quote

Anonymous

Guest
This company let go a lot of good people. Now they are key on launching something new in the hospital in the future. This will fail miserably for two major reasons. The first reason is that all the top performing HSS reps are interviewing and looking for new jobs. The second reason is that not one single top performing rep wants their name attached to Mallinckrodt. Mallinckrodt's name is dirt in the eyes of every single pharmacy department in the United States as well as leading physicians and surgeons. It would be pure hell and career suicide to attempt to launch anything new with the name Mallinckrodt attached to it.
 


















This isn't new information. Anyone with half a brain is looking so they can leave. New drug or device? Here? Hell, no! No one wants anything to sell that's tied in with this company.
 












And good riddance to a dead weight division. Say hi to your OSS counterparts when we let you go. ARD is the only viable AND profitable division which is why our stock price remains high. Life is good when your on the greener side of the fence.
 






Anonymous said:
And good riddance to a dead weight division. Say hi to your OSS counterparts when we let you go. ARD is the only viable AND profitable division which is why our stock price remains high. Life is good when your on the greener side of the fence.
Click to expand...

Oh pleeeeaaaaaase. Give it a rest freak. If you're legitimately a part of the ARD division then you don't know shit about us. The bottom line is you don't. Some of the Ofirmev reps are incredibly damn good reps who did an incredible job laughing this product and keeping the business. The track record of these reps can't be denied and I'm sure they are much better than yours. So go away trash. More than likely you are from the OSS side trying to stir the pot. The pot has already been stirred. This is a shit company and no one wants to work here anymore.
 












Anonymous said:
And good riddance to a dead weight division. Say hi to your OSS counterparts when we let you go. ARD is the only viable AND profitable division which is why our stock price remains high. Life is good when your on the greener side of the fence.
Click to expand...

News Flash!! The stock is dropping like a rock. What is up with that?
 












Anonymous said:
The market is down genius
Click to expand...

Oh and you think this place is viable? Geeeesh. This place is a sinking ship. A smart company brings in the power sellers and launchers and rewards them handsomely. A company is only as good as its sales force. Cadence didn't just hire anyone to fill a slot. This company will continue to be an epic fail from this point on because they have told the entire organization that they WANT CONFORMITY AND MEDIOCRITY. All the people you saw up on that President's Club stage will be gone before the end of the year. After my district meeting? New all sat around a table sharing company leads and recruiters. No one of quality will be staying here. This is not the type of organization that says we hire the best of the best.
 
























Anonymous said:
Aaaahhhh! Don't take it so serious! Who cares. Everything is out of our control.
Click to expand...

The only thing I take serious is making money. It's not out of our control when we can buy put options. That's what I've been doing for the last couple of months. Do you have any idea how much money you can make with options with a 15-20 point stock move. AND you can do it both ways.
 






Respectfully, I think you have the doomsday scenario wrong. Being focused, dare I say, positive with all the appropriate procedural growth expected (with or without you) in both, IN and OUT patient will bring the revenue they expect from Ofirmev. As is without any new data, or IV combos or presentations.

Yeah, the need, the pain management gap is not going away. And you need a sales force for this at this critical & dare I say again, forward looking stage.
 






Anonymous said:
Respectfully, I think you have the doomsday scenario wrong. Being focused, dare I say, positive with all the appropriate procedural growth expected (with or without you) in both, IN and OUT patient will bring the revenue they expect from Ofirmev. As is without any new data, or IV combos or presentations.

Yeah, the need, the pain management gap is not going away. And you need a sales force for this at this critical & dare I say again, forward looking stage.
Click to expand...

What planet do you live on? Tell me again.
 






Anonymous said:
Respectfully, I think you have the doomsday scenario wrong. Being focused, dare I say, positive with all the appropriate procedural growth expected (with or without you) in both, IN and OUT patient will bring the revenue they expect from Ofirmev. As is without any new data, or IV combos or presentations.

Yeah, the need, the pain management gap is not going away. And you need a sales force for this at this critical & dare I say again, forward looking stage.
Click to expand...

If you think Mallinckrodt has the slightest chance of getting any of this done, with the current leadership team--crackerjack sales force or no--you really do live on another planet.
 


















Top Bottom
Back
Quote